YUMMER1.7 Syngeneic Model Overview

The YUMMER1.7 syngeneic model is an immunogenic variant of the YUMM1.7 melanoma line, derived from C57BL/6 mice. It was developed by exposing the parental YUMM1.7 cells to ultraviolet (UV) irradiation, resulting in an increased mutational load and enhanced tumor immunogenicity. This modification makes YUMMER1.7 one of the most valuable preclinical systems for studying immune checkpoint blockade, tumor microenvironment remodeling, and mechanisms of immune escape.

When implanted subcutaneously into immunocompetent C57BL/6 mice, YUMMER1.7 cells generate moderately growing, well-vascularized tumors characterized by abundant immune cell infiltration and reproducible kinetics. Compared with the parental YUMM1.7 line, this model exhibits higher baseline immunogenicity and a more robust response to immune checkpoint inhibitors. YUMMER1.7 therefore provides a clinically relevant system for evaluating immunotherapies in the context of genetically defined, mutation-driven melanoma.

Request a Custom Quote for YUMMER1.7 Syngeneic Model

Biological and Molecular Characteristics

The YUMMER1.7 cell line originates from the YUMM1.7 melanoma model, which carries engineered mutations in Braf, Pten, and Cdkn2a. Following UV mutagenesis, YUMMER1.7 acquired a higher tumor mutational burden, resulting in the formation of neoantigens and stronger activation of anti-tumor immunity. The model retains the signaling features of its parental line—MAPK and PI3K-AKT pathway activation—while gaining enhanced immunogenic potential and responsiveness to cytokine and checkpoint inhibitor therapy.

The tumor microenvironment of YUMMER1.7 is rich in CD8-positive T cells, dendritic cells, and macrophages, accompanied by a diverse array of cytokines including IFN-gamma, IL-6, and TNF-alpha. This immune-active composition promotes measurable inflammation and allows mechanistic studies of T-cell recruitment, antigen presentation, and immune resistance.

Parameter	Description
Host strain	C57BL/6 (female, 6–8 weeks)
Tumor origin	UV-mutagenized melanoma derived from YUMM1.7
Histological type	Poorly differentiated melanoma
Inoculation route	Subcutaneous or orthotopic (intradermal)
Tumor take rate	>90%
Doubling time	Approximately 4–6 days in vivo
Metastatic potential	Moderate; occasional lung involvement
Immunophenotype	Highly immunogenic; strong T-cell and macrophage infiltration
Common applications	Immunotherapy, checkpoint blockade, cytokine studies, immune resistance research

In Vivo Model Development and Tumorigenicity

The YUMMER1.7 model is established through subcutaneous inoculation of tumor cells into C57BL/6 mice, forming visible nodules within one week of implantation. The tumors grow at a moderate rate, allowing detailed longitudinal assessment of immune dynamics and therapy response. Orthotopic implantation into the dermis or ear pinna can be used to model primary melanoma in a native tissue environment, enabling concurrent analysis of local immune infiltration and tumor regression.

This model demonstrates strong sensitivity to immune modulation, with consistent induction of interferon-stimulated pathways and cytotoxic T-cell activation following immunotherapy. YUMMER1.7’s elevated immunogenicity and defined genetic background make it particularly effective for testing combination strategies that merge checkpoint blockade, targeted inhibition, and cytokine therapy.

Request a Custom Quote for YUMMER1.7 Syngeneic Model

Histopathology and Immunohistochemical Profile

Histological evaluation of YUMMER1.7 tumors reveals densely cellular melanomas composed of spindle and polygonal cells with moderate pigmentation. The tumor parenchyma is interspersed with inflammatory infiltrates and displays a well-developed vascular network. Compared with YUMM1.7, YUMMER1.7 tumors exhibit increased lymphocytic infiltration and a more heterogeneous stromal architecture, consistent with active immune engagement.

Immunohistochemical staining confirms abundant CD3 and CD8-positive T-cell infiltration throughout the tumor parenchyma and perivascular regions. F4/80 and CD11b staining demonstrate macrophage and myeloid cell presence, while PD-L1 is strongly expressed on both tumor and infiltrating immune cells. Ki-67 staining indicates steady proliferation, and p-ERK positivity reflects continued MAPK pathway activity. The combination of defined oncogenic signaling and strong immune activation underscores YUMMER1.7’s suitability for translational immunotherapy research.

Preclinical Applications and Drug Response

The YUMMER1.7 syngeneic model has become a benchmark for testing immune checkpoint inhibitors, cytokine therapies, and combination regimens in melanoma. It exhibits robust responses to PD-1 and CTLA-4 blockade, leading to significant tumor regression and durable immune memory in a subset of animals. The model’s immunogenic nature also makes it an excellent system for evaluating cancer vaccines, oncolytic viral therapy, and adoptive T-cell approaches.

YUMMER1.7 has been used extensively to study mechanisms of acquired resistance to immunotherapy and the role of tumor mutational burden in shaping immune responsiveness. Combination treatments involving BRAF or MEK inhibitors with checkpoint blockade have demonstrated synergistic efficacy, offering translational insights relevant to human melanoma management. Its defined genetic background, strong immune engagement, and reproducible tumor kinetics make YUMMER1.7 one of the most advanced murine systems for preclinical immuno-oncology.

Request This Model

To request the YUMMER1.7 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for YUMMER1.7 Syngeneic Model